Quote | Larimar Therapeutics Inc. (NASDAQ:LRMR)
Last: | $9.49 |
---|---|
Change Percent: | 0.8% |
Open: | $9.35 |
Close: | $9.49 |
High: | $9.97 |
Low: | $9.29 |
Volume: | 335,670 |
Last Trade Date Time: | 07/24/2024 03:00:00 am |
News | Larimar Therapeutics Inc. (NASDAQ:LRMR)
2024-07-15 12:03:52 ET More on Lexeo Therapeutics Lexeo Therapeutics reports Q1 results IPO Roundup: Viking Holdings, RanMarine Technology, and more Historical earnings data for Lexeo Therapeutics Financial information for Lexeo Therapeutics Read th...
2024-07-15 03:59:45 ET Summary Larimar Therapeutics' stock has surged 50% after its FA therapy was selected for FDA's START program, aiming for a BLA filing in 2H25. Its lead candidate Nomlabofusp is a protein replacement therapy for Friedreich's ataxia, competing with Biogen's Sk...
Message Board Posts | Larimar Therapeutics Inc. (NASDAQ:LRMR)
Subject | By | Source | When |
---|---|---|---|
could probably get through approval on just 25 | magacrew2020 | investorshub | 02/28/2023 11:21:47 PM |
znewcar1: LRMR 24% v2,7M c2.89 f17,7M H3.58 ML1.53 | znewcar1 | investorshangout | 08/19/2022 12:18:48 AM |
The company said it received feedback from the | subslover | investorshub | 08/12/2022 12:58:00 PM |
I voted NO on the 2022 Annual Meeting | JJJ54 | investorshub | 04/21/2022 1:11:30 AM |
Interesting. | DarkPool | investorshub | 02/14/2022 10:08:23 PM |
News, Short Squeeze, Breakout and More Instantly...
Larimar Therapeutics Inc. Company Name:
LRMR Stock Symbol:
NASDAQ Market:
Larimar Therapeutics Inc. Website:
2024-07-06 15:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseases Nomlabofusp was selected based on potential for clinical benefit in a rare neurodegenerative disease and demonstrated development pro...
2024-05-29 08:45:00 ET Growth stocks have been outpacing value and dividend stocks since 2008, and this performance gap has only widened as the pandemic's impact has waned. Technological breakthroughs are opening new markets in high-demand areas, fueling investor interest in a wide array of...